Literature DB >> 6296843

Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

L D Cahan, R F Irie, R Singh, A Cassidenti, J C Paulson.   

Abstract

Two monospecific human antibodies (anti-OFA-I-1 and anti-OFA-I-2) produced in vitro by lymphoblast cell lines originating from melanoma patients have been shown previously to recognize cell surface antigens (OFA-I-1 and OFA-I-2) on human tumors and fetal brain: OFA-I-1 is expressed on a variety of human tumors, while OFA-I-2 has been detected only on tumors of neuroectodermal origin. Evidence presented in this report suggests that the two antigens expressed by a cultured human melanoma cell line (M14) are chemically distinct and that OFA-I-2 is a cell surface glycolipid, ganglioside GD2: GalNAc beta 1 leads to 4 NeuAc alpha 2 leads to 8NeuAc alpha 2 leads to 3 Gal beta 1 leads to 4Glc-ceramide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6296843      PMCID: PMC347401          DOI: 10.1073/pnas.79.24.7629

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Structures and organization of cell surface glycolipids dependency on cell growth and malignant transformation.

Authors:  S Hakomori
Journal:  Biochim Biophys Acta       Date:  1975-03-20

2.  Lacto-N-neotetraosylceramide ("paragloboside") as a possible tumor-associated surface antigen of hamster NILPY tumor.

Authors:  J S Sundsmo; S Hakomori
Journal:  Biochem Biophys Res Commun       Date:  1976-02-09       Impact factor: 3.575

3.  Altered ganglioside biosynthesis in mouse cell cultures following transformation with chemical carcinogens and x-irradiation.

Authors:  P L Coleman; P H Fishman; R O Brady; G J Todaro
Journal:  J Biol Chem       Date:  1975-01-10       Impact factor: 5.157

4.  Action of neuraminidase (EC 3.2.1.18) from Clostridium perfringens on brain gangliosides in the presence of bile salts.

Authors:  D A Wenger; S Wardell
Journal:  J Neurochem       Date:  1973-02       Impact factor: 5.372

5.  Possible immunological factors in human malignant melanoma in Uganda.

Authors:  M G Lewis
Journal:  Lancet       Date:  1967-10-28       Impact factor: 79.321

6.  [On a component of the mixture of brain gangliosides, which is transferred to the Tay-Sachs ganglioside under the influence of neuraminidase].

Authors:  E Klenk; M Naoi
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1968-03

7.  Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction.

Authors:  G Klein; P Clifford; E Klein; J Stjernswärd
Journal:  Proc Natl Acad Sci U S A       Date:  1966-06       Impact factor: 11.205

Review 8.  Sialic acids: their analysis and enzymic modification in relation to the synthesis of submandibular-gland glycoproteins.

Authors:  R Schauer; H P Buscher; J Casals-Stenzel
Journal:  Biochem Soc Symp       Date:  1974

9.  Blood group MN precursors as human breast carcinoma-associated antigens and "naturally" occurring human cytotoxins against them.

Authors:  G F Springer; P R Desai; E F Scanlon
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

10.  Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells.

Authors:  K Irie; R F Irie; D L Morton
Journal:  Science       Date:  1974-11-01       Impact factor: 47.728

View more
  42 in total

1.  Subcellular biosynthesis and transport of gangliosides formed from exogenous lactosylceramide in rat liver.

Authors:  M Trinchera; R Ghidoni
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

2.  The N-acetylgalactosamine residue of exogenous GM2 ganglioside is recycled for glycoconjugate biosynthesis in rat liver.

Authors:  M Trinchera; R Ghidoni; L Greggia; G Tettamanti
Journal:  Biochem J       Date:  1990-02-15       Impact factor: 3.857

3.  Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody.

Authors:  P B Chapman; A N Houghton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Chemoenzymatic galactosialylation with integrated cofactor regeneration.

Authors:  P Stangier; W Treder; J Thiem
Journal:  Glycoconj J       Date:  1993-02       Impact factor: 2.916

5.  Human melanoma-associated antigen expression on human neuroblastoma cells: effects of differentiation inducers.

Authors:  V Feyles; W T Dixon; L K Sikora; R C McGarry; L M Jerry
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Cellular immuno-PCR. Detection of a carbohydrate tumor marker.

Authors:  Z Zhang; R F Irie; D D Chi; D S Hoon
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

7.  Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

Authors:  P O Livingston; E J Natoli; M J Calves; E Stockert; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates.

Authors:  P Hersey; A Edwards; A Coates; H Shaw; W McCarthy; G Milton
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.

Authors:  D C Longee; C J Wikstrand; J E Månsson; X He; G N Fuller; S H Bigner; P Fredman; L Svennerholm; D D Bigner
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 10.  The current state of immunotherapy for primary and secondary brain tumors: similarities and differences.

Authors:  Takahide Nejo; Abigail Mende; Hideho Okada
Journal:  Jpn J Clin Oncol       Date:  2020-10-22       Impact factor: 3.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.